ABL, Inc. and CALIXAR Announced Strategic Marketing Agreement

October 1, 2013

ABL will extend the capabilities of its vaccine and biologics therapeutic development services by offering CALIXAR’s innovative process for native extraction and purification of membrane proteins and antigens that avoid the necessity of re

Share this post

Secure and boost
your discovery programs

Starting from native material or recombinant systems, we succeed with all types of proteins: Kinases, Phosphatases, Ubiquitins, Epigenetic Proteins, GPCRs, Ion Channels, Transporters, Receptors and Viral Proteins.